Selective Estrogen Receptor Modulators and Breast Cancer Prevention
Author Information
Author(s): Namba Ruri, Young Lawrence JT, Maglione Jeannie E, McGoldrick Erik T, Liu Stephenie, Wurz Gregory T, DeGregorio Michael W, Borowsky Alexander D, MacLeod Carol L, Cardiff Robert D, Gregg Jeffrey P
Primary Institution: University of California, Davis
Hypothesis
Can selective estrogen receptor modulators inhibit the growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ?
Conclusion
Tamoxifen and ospemifene inhibit the growth of premalignant mammary lesions and the progression to invasive carcinoma in a transplantable mouse model of DCIS.
Supporting Evidence
- The MIN-O was ER-positive and ovarian ablation resulted in reduced MIN-O growth and tumor development.
- Tamoxifen and ospemifene treatments decreased the MIN growth and tumor incidence in comparison with the control.
- Both SERMs significantly decreased cell proliferation.
Takeaway
This study shows that two medications, tamoxifen and ospemifene, can help stop early breast cancer from getting worse in mice.
Methodology
The study used a mouse transplantation model of ductal carcinoma in situ to assess the effects of tamoxifen and ospemifene on tumor growth and incidence.
Limitations
The study is limited to a mouse model, which may not fully replicate human breast cancer behavior.
Participant Demographics
Three-week-old female FVB/J mice were used in the study.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website